Teleflex 3Q 2026: Revenue $567.78M, EPS $22.28 — 10-Q Summary
Teleflex reported 3Q 2026 revenue of $567.78M, flat year-over-year, with net income of $927.43M, driven by a gain on its OEM business sale. Vascular and Surgical segments grew, while Interventional declined. The company expects to complete the sale of its Acute Care and Interventional Urology business by year-end 2026 or early 2027.
How this was made
The 30-second read
Why it matters
The earnings beat and cash proceeds are likely to trigger short‑term buying, though investors should watch for guidance on upcoming Interventional Urology sale.
Market read
First‑time earnings disclosure with material profit swing; actionable for traders monitoring mid‑cap healthcare stocks.
What to watch
Potential integration costs of remaining businesses and exposure to foreign‑exchange volatility.
Background
Teleflex filed its Form 10‑Q for Q3 2026, highlighting a flat revenue trend but a dramatic net‑income swing due to a divestiture.
Ticker impact
Teleflex reported Q3 2026 revenue of $567.78M (flat YoY) and a swing to $927.43M net income, driven by a $1.0B pretax gain on its OEM divestiture.
upside pressure as the market prices in the earnings beat and one‑time gain.
First‑time disclosure of a large profit swing and a $1.5B cash proceeds from a divestiture, both material for a mid‑cap medical device company.
Market effects
May lift other medical‑device peers as the OEM divestiture signals consolidation trends.
U.S. healthcare sector could see modest buying pressure.
Limited to U.S. and global medical‑device investors.
Counterpoint
The profit boost is one‑time; future quarters may revert to lower earnings, suggesting caution.
Key entities
- CompanyTeleflex Inc.
Medical‑device manufacturer (ticker TFX).
